AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting

SHENZHEN,China,April 19,2023 --On April 18,2023,U.S. time,ImmVira presented preclinical study results of CAR-T enabler oHSV product MVR-7011 through poster publication at the American Association for Cancer Research ("AACR") annual meeting.

Solid tumor has long been a challenge for CAR-T therapies. At present,most of the research efforts continue to focus on further modification of CAR-T cells,while ImmVira takes a new approach – using oHSV as vector to safely and stably deliver biomarkers that are demonstrated success in CAR-T treatment of hematologic malignancies to be precisely expressed on target tumor cell membranes for a long and continuous time window. A breakthrough advantage is that current CAR-T therapies originally targeting blood cancer can be enabled on solid tumors without any modifications required. MVR-T7011 is designed to continuously and precisely express extracellular domains of CD19 and BCMA as "biomarker" on the cell membranes of solid tumors to provide targets for CAR-T treatment,and also carry chemokine CCL5,PD-1 antibody and IL-12 genes to further enhance the killing effects on tumor cells.

At the AACR meeting,ImmVira presented the main preclinical study results of MVR-T7011 for the first time. In the preclinical studies conducted by ImmVira,MVR-T7011 specifically deliver and continuously express CD19 and BCMA on the tumor cell surface,while these biomarkers were not detected in normal tissues,ensuring its safety for use in combination with CAR-T therapy. Similarly,the payload of CCL5,IL-12,and anti-PD-1 antibody showed a comparable expression pattern. In vitro toxicity and co-culture experiments demonstrated that MVR-T7011 did not affect the viability nor impair the proliferation of CAR-T cells and can specifically enhance their cell-killing activity on tumor cells. Results from in vivo efficacy tests demonstrated that both intratumoral (IT) and intraperitoneal (IP) administration of MVR-T7011 can activate CAR-T cell proliferation,leading to synergistic antitumor effects against various solid tumors.

ImmVira's unique approach to modifying the tumor environment paves way for a large range of current and future emerging cancer therapies. MVR-T7011 can effectively resolve current difficulty of target heterogeneity and escape in CAR-T treatment of solid tumors through specific expression of CD19 and BCMA at the tumor site and also promote proliferation of CAR-T cells to extend treatment time window. This combination therapy is expected to help CAR-T broaden clinical application from blood to solid cancer. ImmVira has completed in-house pilot-scale manufacturing of MVR-T7011 and launched preclinical study. In the future,ImmVira will start IND filing preparation once reaching strategic partnership.

About ImmVira

ImmVira is a biotechnology company focused on developing and synthesizing biological vector delivery platform. The company has constructed a fully integrated OVPENS (Open Vector+ Potent,Enabling,Novel & Safe) platform with solid science,technology and CMC know-how,and three derivative subplatforms including Oncolytic Virus,Cancer Vaccine and Biosynthetic Exosome,to support ongoing R&D,clinical studies and commercialization of best-in-class mono and combo therapies driven by clinical benefits in oncology and non-oncology fields.